Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modelling clustered survival data from multicentre clinical trials.

David V Glidden1, Eric Vittinghoff

  • 1Department of Epidemiology and Biostatistics, University of California-San Francisco, 500 Parnassus Avenue, MU-420 West, Box 0560, San Francisco, CA 94143-0560, U.S.A. dave@biostat.ucsf.edu

Statistics in Medicine
|January 30, 2004
PubMed
Summary

Analyzing multicentre trial data requires accounting for center effects. The gamma frailty model offers a robust and practical solution for censored time-to-event data analysis, outperforming other methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Rapid Antiretroviral Therapy Restart and HIV Care Relinkage Support at a Sexual Health Clinic in San Francisco.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality.

PloS one·2026

Area of Science:

  • Biostatistics
  • Clinical Trials Methodology
  • Survival Analysis

Background:

  • Multicentre randomized clinical trials involve subjects from various study locations.
  • Factors that differ across these centres can significantly impact study outcomes.
  • Incorporating these centre effects into the analysis of censored time-to-event data is a common challenge.

Purpose of the Study:

  • To survey methods for analyzing censored time-to-event data in multicentre trials.
  • To identify and evaluate advantageous approaches for incorporating centre effects.
  • To highlight the utility of the gamma frailty model for this purpose.

Main Methods:

  • Survey of existing statistical methods for handling centre effects in survival analysis.
  • Evaluation of the gamma frailty model for analysing censored time-to-event data from multicentre trials.

Related Experiment Videos

  • Assessment of the model's performance and robustness, including sensitivity to the frailty distribution assumption.

    • Main Results:

    • The gamma frailty model demonstrates substantial advantages over competing methods.
    • This approach is minimally affected by violations of the gamma-distributed frailty assumption.
    • Recent computational advancements make the gamma frailty model a practical tool.

    Conclusions:

    • The gamma frailty model is a practical and appealing tool for addressing centre effects in multicentre trials.
    • It offers a robust and effective method for analysing censored time-to-event data.
    • This model provides a favourable comparison to alternative analytical approaches.